MedTrace Logo

Multidrug Resistant Shigella Infection in Bangladesh

NCT03778125 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2019-01-29

No results posted yet for this study

Summary

The purpose of this project is to systematically collect clinical and nutritional outcomes information on patients treated for Shigella infection so that physicians and clinical laboratories can better define which Shigella infections are "resistant" to antibiotics and which are "susceptible", focusing on azithromycin a last-line drug to treat drug resistant Shigella

Conditions

Sponsors & Collaborators

Principal Investigators

  • Eric R Houpt, MD · University of Virginia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2019-12-31
Completion
2020-01-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778125 on ClinicalTrials.gov